GLOW Blend Research Guide: GHK-Cu, BPC-157 & TB-500 Synergy

What Is GLOW Blend?

GLOW (catalog code GLOW70) is not a single molecule. It is a proprietary, co-lyophilized blend of three distinct research peptides — GHK-Cu, BPC-157 and TB-500 — combined in a fixed 50/10/10 mg mass ratio in one vial. Because it is a mixture of three different sequences rather than one compound, GLOW has no single molecular weight and no single CAS number; each component has to be characterized individually.

The reason these three were grouped together is mechanistic. Each maps onto one of the three classical arms of tissue repair: GHK-Cu drives extracellular-matrix (ECM) synthesis and remodeling, BPC-157 is associated with angiogenesis and vascular support, and TB-500 (a thymosin β4 fragment) drives actin-based cell migration. Pulling all three into one preparation makes GLOW a convenient input for in-vitro studies of combined, multi-pathway peptide interactions.

Mechanism of Action

GLOW's design logic is that its three peptides act on complementary, non-redundant repair pathways. Below is what each component does on its own; the combined "synergy" is a rationale built from those individual mechanisms, not a measured combined effect (more on that in the literature section).

GHK-Cu → Matrix

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (free tripeptide GHK: C₁₄H₂₄N₆O₄, ~340.4 Da, PubChem CID 73587; the active copper complex is commonly cited as CAS 49557-75-7 — note that CAS numbers differ by form, i.e. free peptide vs acetate salt vs Cu complex). GHK was first isolated from human plasma in 1973, and plasma levels fall from roughly 200 to 80 ng/mL between ages 20 and 60. As a copper chaperone and fibroblast signal, it up-regulates collagen, elastin and glycosaminoglycan synthesis and broadly modulates wound-repair gene programs. Net role in the blend: it builds and remodels the ECM scaffold.

BPC-157 → Vasculature

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide, sequence GEPPPGKPADDAGLV (C₆₂H₉₈N₁₆O₂₂, ~1,419.5 Da, CAS 137525-51-0, PubChem CID 9941957), corresponding to a partial sequence of a protein in human gastric juice. Its three consecutive prolines confer N-terminal rigidity and stability. In muscle and tendon healing models it is associated with modulation of angiogenesis via VEGF up-regulation (an in-vivo, context-dependent effect rather than a direct action on cell cultures alone). Net role in the blend: supporting the vascular supply to the repairing matrix.

TB-500 → Migration

TB-500 here refers to the actin-binding LKKTETQ active region of thymosin β4 — specifically the N-acetylated heptapeptide Ac-LKKTETQ (residues 17–23 of Tβ4, ~889 Da, commonly cited as CAS 77591-33-4). A nomenclature caution applies: across the wider literature and vendor market, "TB-500" is defined two different ways — strictly the Ac-LKKTETQ heptapeptide, but often conflated with full-length thymosin β4 (43 aa, ~4,963 Da). The blend's own label ("TB-500, Thymosin Beta-4 fragment") matches the heptapeptide definition, and the active region is LKKTETQ. Thymosin β4 is the principal intracellular G-actin–sequestering peptide; that LKKTETQ motif is what drives keratinocyte, fibroblast and endothelial migration. Net role in the blend: mobilizing the actin cytoskeleton to move cells into the wound.

Putting the Three Together

The integration thesis is straightforward: matrix synthesis (GHK-Cu) + new vasculature (BPC-157) + cell migration (TB-500) touch the three core arms of tissue repair. That makes GLOW a hypothesis-generating tool for studying combined-pathway peptide interactions in vitro — but it is a mechanistic rationale, not a demonstrated combined result.

What the Research Literature Reports

An important framing point up front: there is no published controlled study of this specific 50/10/10 GHK-Cu + BPC-157 + TB-500 blend. The "synergy" is assembled from each component's individual preclinical literature; it is not an experimentally validated combination. The findings below describe published work on the individual peptides, almost all of which is in-vitro or animal-model, and none of which is presented as a use indication for research-grade material.

GHK-Cu (ECM / Collagen)

GHK-Cu has the deepest, oldest peer-reviewed base of the three, anchored by the long-running Pickart group. Pickart & Margolina (International Journal of Molecular Sciences, 2018; PMID 29986520) review how GHK-Cu increases collagen, elastin and glycosaminoglycan synthesis and improves tissue repair across skin, lung, bone, liver and stomach lining, with recent gene data showing it regulates many biochemical pathways simultaneously. Pickart, Vasquez-Soltero & Margolina (Oxidative Medicine and Cellular Longevity, 2012; PMID 22666519) describe its wound-healing actions via angiogenesis, anticoagulation and vasodilation, its role as a powerful attractant for capillary cells, and its up- and down-regulation of a large number of human genes. Dou et al. (Aging Pathobiology and Therapeutics, 2020; PMID 35083444) report that GHK-Cu increases bFGF and VEGF expression in human dermal fibroblasts, supports connective-tissue synthesis as a copper source, and accelerates burn-wound healing in mice.

BPC-157 (Angiogenesis / Vascular)

Brcic et al. (Journal of Physiology and Pharmacology, 2009; PMID 20388964) reported that BPC-157 modulates angiogenesis in muscle and tendon healing by up-regulating VEGF expression, noting the effect is in-vivo and context-dependent rather than a direct angiogenic action on cell cultures alone. An evidence-quality caveat is warranted here: the BPC-157 literature is dominated by a single research group (Sikiric and colleagues), the peptide has no regulatory approval, and human data are limited. That single-lab concentration is worth weighting when interpreting how robust the body of evidence is.

TB-500 / Thymosin β4 (Cytoskeletal / Migration)

The cytoskeletal basis is well established. Safer, Elzinga & Nachmias (Journal of Biological Chemistry, 1991; PMID 1999398) showed that thymosin β4 is indistinguishable from the actin-sequestering peptide "Fx," establishing Tβ4 as a primary regulator of the G-actin pool that underlies cell motility. Philp et al. (FASEB Journal, 2003; PMID 14500546) demonstrated that the seven-amino-acid actin-binding motif (the LKKTETQ region that defines TB-500) is essential for the angiogenic activity of Tβ4, including endothelial adhesion and sprouting. On the in-vivo migration side, Malinda et al. (Journal of Investigative Dermatology, 1999; PMID 10469335) reported that thymosin β4 accelerated wound healing in a rat full-thickness model — increasing re-epithelialization by 42% at day 4 and up to 61% at day 7 versus saline controls, with greater wound contraction.

Overall evidence strength: preclinical and limited. GHK-Cu has the strongest base, BPC-157's data carry the single-lab caveat above, and the TB-500 heptapeptide rests largely on the parent-protein mechanism. Critically, the blend itself remains unstudied as a combination — treat any "synergy" claim as complementary-mechanism rationale, not proven combined efficacy.

Reconstitution & Handling for Research

GLOW ships as a single co-lyophilized cake containing all three peptides, so all three dissolve together in one reconstitution step — you cannot separate or independently prepare the components once the vial is mixed.

• Storage of the lyophilized blend. Keep the sealed vial refrigerated (2–8 °C), protected from light; for long-term storage, −20 °C. Lyophilized peptides are far more stable than solutions.
• Solvent. The standard solvent for lyophilized research peptides is Bacteriostatic Water for Injection, USP — sterile water with 0.9% (9 mg/mL) benzyl alcohol as a bacteriostatic preservative, which permits multi-draw use over an extended window (commonly cited up to ~28 days at 2–8 °C; this is a general bacteriostatic-water property, not blend-specific stability data). Sterile Water for Injection, USP can be used where a single-use, preservative-free solution is preferred.
• Add solvent gently — do not shake. Add diluent slowly down the vial wall; do not inject directly onto the cake. Swirl gently or let it dissolve passively. Vigorous shaking or vortexing creates shear and foaming that can denature peptides.
• Expect a blue/teal tint. GHK-Cu in solution typically carries a characteristic blue/teal color from the copper(II) complex — this is normal for this blend.
• Mild acidification (only if needed). Some lyophilized peptides reconstitute more completely with a brief, mild acetic-acid-in-water step before bacteriostatic water. Use it only if a component does not fully clear.
• After reconstitution. Store the solution refrigerated (2–8 °C), protected from light; avoid repeated freeze–thaw. Inspect for clarity and discard if cloudy or particulate.

Because the 50/10/10 mass ratio is fixed, the concentration of each component is set entirely by your chosen solvent volume. As an illustrative (not prescriptive) example, dissolving in 2 mL yields a nominal 25 mg/mL GHK-Cu, 5 mg/mL BPC-157 and 5 mg/mL TB-500. Those figures are simple arithmetic from the stated spec and volume.

GLOW Blend vs Its Three Components

The practical question many researchers ask is whether to use the blend or buy the three peptides separately. The trade-off comes down to fixed convenience versus ratio control.

• Pathway coverage in one step. GLOW co-delivers all three repair arms — ECM remodeling (GHK-Cu), angiogenesis (BPC-157) and actin-driven migration (TB-500) — in fixed proportion in a single vial and a single reconstitution. Buying components separately lets you set arbitrary independent ratios and dissolve/store each on its own, at the cost of more vials and more steps.
• Fixed ratio. The 50/10/10 mass ratio is locked once reconstituted, with GHK-Cu dominating by mass (5× each of the others). Single peptides give full ratio control; the blend gives a pre-defined "matrix + vessels + migration" composition for combination-interaction studies.
• Distinct molecular identities. This is why the blend has no single MW: the three differ by roughly 4× in size — GHK-Cu (~340 Da peptide / Cu complex), TB-500 heptapeptide (~889 Da) and BPC-157 (~1,419 Da). Characterize and quantify each individually (e.g., HPLC purity per component), never as one analyte.

For component-level depth, the standalone research guides go deeper than this overview: see the GHK-Cu research guide, the BPC-157 research guide, the TB-500 research guide, and the head-to-head BPC-157 vs TB-500 comparison.

Evaluating Research-Grade Supply

For reproducible work with a multi-peptide blend, analytical documentation matters even more than with a single compound — you are verifying three sequences, not one. When sourcing GLOW for research, look for:

1. Per-Component COA Characterization

Because GLOW is three molecules, a meaningful Certificate of Analysis cannot treat it as a single analyte. A legitimate vendor provides a batch-specific COA, ideally from an independent lab, that addresses the components individually:

• HPLC purity per component — each peptide quantified separately rather than as one lumped peak.
• Mass-spec confirmation — verifying each sequence's expected mass (~340 Da GHK / Cu complex, ~889 Da TB-500 heptapeptide, ~1,419 Da BPC-157), which is how you confirm you received the intended three peptides and not a truncated or mislabeled sequence.
• Batch / lot number and a recent test date linking the COA to your specific vial.

Elytra Labs publishes batch-specific third-party COAs for the research peptides we ship. Browse our current COA library → and see our guide to reading a peptide COA for how to interpret chromatogram and mass-spec data — especially useful when a single document has to cover more than one sequence.

2. Lyophilized Form and Cold-Chain Discipline

GLOW should arrive as a lyophilized powder. Keep it cold and sealed until reconstitution, and reconstitute with clean bacteriostatic water as described above. A vendor that ships it properly and documents handling guidance is doing real quality control, not just shipping powder. For broader stack-level context, our guide to peptide stacks covers how combination preparations are framed in research.

Frequently Asked Research Questions

Does GLOW Blend have a single molecular weight?

No. GLOW is a proprietary blend of three peptides — GHK-Cu, BPC-157 and TB-500 in a 50/10/10 mg ratio — so it has no single molecular weight and no single CAS number. Each component is characterized separately (GHK-Cu free peptide ~340.4 Da, TB-500 heptapeptide ~889 Da, BPC-157 ~1,419.5 Da).

What does the "synergy" between the three components actually mean?

It is a mechanistic rationale, not a tested result. The idea is that the three hit complementary repair pathways — GHK-Cu builds extracellular matrix, BPC-157 supports angiogenesis, and TB-500 drives actin-based cell migration — together covering the core arms of tissue repair. No published controlled study exists for this specific 50/10/10 combination, so any synergy claim should be read as complementary-mechanism reasoning, not demonstrated combined efficacy.

Which definition of "TB-500" does GLOW use?

"TB-500" is defined two ways in the wild — strictly the Ac-LKKTETQ heptapeptide (~889 Da, residues 17–23 of thymosin β4), but often sold or described as full-length thymosin β4 (43 aa, ~4,963 Da). The blend's label, "TB-500 (Thymosin Beta-4 fragment)," matches the heptapeptide definition; the active region in either case is the LKKTETQ actin-binding motif (Philp et al., 2003, PMID 14500546).

Can the three peptides be dosed independently once GLOW is reconstituted?

No. GLOW is a single co-lyophilized cake, so all three dissolve together and the 50/10/10 ratio is fixed the moment it is reconstituted. If a research design needs independent control of each component's ratio, that calls for buying the three single peptides separately rather than using the blend.

What does "research-grade" mean here?

It indicates the material is intended for laboratory in vitro and animal-model investigation, synthesized in an appropriate facility, and accompanied by analytical documentation (per-component purity, mass spec, batch records). It is not pharmaceutical- or human-grade; none of the three components is approved for human or veterinary therapeutic use, and BPC-157 and TB-500 in particular have no regulatory approval.